Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ip Group Plc LSE:IPO London Ordinary Share GB00B128J450 ORD 2P
  Price Change % Change Share Price Shares Traded Last Trade
  1.00 0.75% 134.40 2,125,288 16:29:00
Bid Price Offer Price High Price Low Price Open Price
134.20 134.60 135.00 133.40 133.40
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 186.10 17.47 7.7 1,428
Last Trade Time Trade Type Trade Size Trade Price Currency
18:09:20 O 2 134.40 GBX

Ip (IPO) Latest News

More Ip News
Ip Investors    Ip Takeover Rumours

Ip (IPO) Discussions and Chat

Ip Forums and Chat

Date Time Title Posts
16/4/202110:45IP Group PLC1,037
02/4/202114:09ONT future steps.2
23/12/202009:51IP Group - commercialising university technology.971
11/10/201207:43::: The DIRECT LINE IPO :::83
08/11/201007:59IP 2 IPO, digging up value, from the boffins.213

Add a New Thread

Ip (IPO) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Ip trades in real-time

Ip (IPO) Top Chat Posts

DateSubject
18/4/2021
09:20
Ip Daily Update: Ip Group Plc is listed in the General Financial sector of the London Stock Exchange with ticker IPO. The last closing price for Ip was 133.40p.
Ip Group Plc has a 4 week average price of 118.40p and a 12 week average price of 89.80p.
The 1 year high share price is 135p while the 1 year low share price is currently 48p.
There are currently 1,062,353,734 shares in issue and the average daily traded volume is 3,214,731 shares. The market capitalisation of Ip Group Plc is £1,427,803,418.50.
11/4/2021
20:35
bamboo2: wba, this is the info on valuations from the last results. Hinge Health latest round [6/1/2021] was post period, therefore not included in the latest results. =============================== Fair value hierarchy The Group classifies financial assets using a fair value hierarchy that reflects the significance of the inputs used in making the related fair value measurements. The level in the fair value hierarchy, within which a financial asset is classified, is determined on the basis of the lowest level input that is significant to that asset's fair value measurement. The fair value hierarchy has the following levels: Level 1 - Quoted prices in active markets. Level 2 - Inputs other than quoted prices that are observable, such as prices from market transactions. Level 3 - One or more inputs that are not based on observable market data. Equity investments Fair value is the underlying principle and is defined as "the price that would be received to sell an asset in an orderly transaction between market participants at the measurement date" (IPEV guidelines, December 2018). Where the equity structure of a portfolio company involves different class rights in a sale or liquidity event, the Group takes these different rights into account when forming a view on the value of its investment. Valuation techniques used The fair value of unlisted securities is established using appropriate valuation techniques in line with IPEV guidelines and including IPEV's special guidance issued in March 2020 in response to Covid-19. The selection of appropriate valuation techniques is considered on an individual basis in light of the nature, facts and circumstances of the investment and in the expected view of market participants. The Group selects valuation techniques which make maximum use of market-based inputs. Techniques are applied consistently from period to period, except where a change would result in better estimates of fair value. Multiple valuation techniques may be used so that the results of one technique may be used as a cross check/corroboration of an alternative technique. Valuation techniques used include: -- Quoted investments: the fair values of quoted investments are based on bid prices in an active market at the reporting date. -- Milestone approach: an assessment is made as to whether there is an indication of change in fair value based on a consideration of the relevant milestones typically agreed at the time of making the investment decision. -- Scenario analysis: a forward-looking method that considers one or more possible future scenarios. These methods include simplified scenario analysis and relative value scenario analysis, which tie to the fully diluted ("post-money") equity value, as well as full scenario analysis vie the use of the probability-weighted expected return method (PWERM). -- Current value method: the estimation and allocation of the equity value to the various equity interests in a business as though the business were to be sold on the Measurement Date. -- Discounted cash flows: deriving the value of a business by calculating the present value of expected future cash flows. -- Multiples: the application of an appropriate multiple to a performance measure (such as earnings or revenue) of the Investee Company in order to derive a value for the business. The fair value indicated by a recent transaction is used to calibrate inputs used with valuation techniques including those noted above. At each measurement date, an assessment is made as to whether changes or events subsequent to the relevant transaction would imply a change in the investment's fair value. The Price of a Recent Investment is not considered a standalone valuation technique (see further considerations below). Where the current fair value of an investment is unchanged from the price of a recent financing, the group refers to the valuation basis as 'Recent Financing'. Price of recent investment as an input in assessing fair value The Group considers that fair value estimates which are based primarily on observable market data will be of greater reliability than those based on assumptions. Given the nature of the Group's investments in seed, start-up and early-stage companies, where there are often no current and no short-term future earnings or positive cash flows, it can be difficult to gauge the probability and financial impact of the success or failure of development or research activities and to make reliable cash flow forecasts. Consequently, in many cases the most appropriate approach to fair value is a valuation technique which is based on market data such as the price of a recent investment, and market participant assumptions as to potential outcomes. Calibrating such scenarios or milestones may result in a fair value equal to price of recent investment for a limited period of time. Often qualitative milestones provide a directional indication of the movement of fair value. In applying a calibrated scenario or milestone approach to determine fair value consideration is given to performance against milestones that were set at the time of the original investment decision, as well as taking into consideration the key market drivers of the investee company and the overall economic environment. Factors that the Group considers include, inter alia, technical measures such as product development phases and patent approvals, financial measures such as cash burn rate and profitability expectations, and market and sales measures such as testing phases, product launches and market introduction. Where the Group considers that there is an indication that the fair value has changed, an estimation is made of the required amount of any adjustment from the last price of recent investment. Where a deterioration in value has occurred, the Group reduces the carrying value of the investment to reflect the estimated decrease. If there is evidence of value creation the Group may consider increasing the carrying value of the investment; however, in the absence of additional financing rounds or profit generation it can be difficult to determine the value that a market participant may place on positive developments given the potential outcome and the costs and risks to achieving that outcome and accordingly caution is applied.
11/4/2021
13:38
eeza: A very intersesting post from the ORPH (Open Orphan) bb regarding an IPO Co, Hinge Health (IPO = 2.4%). Extrader11 Apr '21 - 13:08 - 14147 of 14148 0 2 0 The wearables market is running 'hot'. See hxxps://www.smallcompanychampion.uk/2021/04/open-orphan-launch-of-disease-in-motion.html Tying in with barwickman's link, here's another , for a US wearables company called HingeHealth, which basically uses the sensors in wearables to deliver accurate physiotherapy at home, to palliate/resolve musculoskeletal problems (back, shoulder, knee) that apparently affect up to 40 % of the US population. Its business proposition is to offer major US corporates (eg Boeing, KraftHeinz, Walgreens) an employee benefit that (a) works and (b) saves the employer money... https://www.nasdaq.com/articles/hinge-health-eyes-ipo-after-raising-%24300-million-2021-01-06 Its January 2021 funding round gives an implied value to HH of $ 3 billion; its Feb 2020 funding round implied $ 428 million.... This is how HH puts it hxxps://www.hingehealth.com/hinge-health-raises-series-d/ For the serial entrepreneur fans out there, it started out life as a would be 'miner' of Samsung's portfolio of patents; pivoted into 'memory foam' furniture' ; and appears to have struck gold at the third iteration. I'll be watching HH's planned 2022 IPO with some interest - a family member has worked there for some time. ;-> Extrader11 Apr '21 - 13:32 - 14148 of 14148 0 1 0 Funnily enough, there's an ORPH tie-up : Business incubator/commercialiser IP Group has 2.4% of HingeHealth ...and Elaine Sullivan as a NED on its board ....and she's also on ORPH's , since Nov 2020. Small world.
02/4/2021
14:01
bamboo2: Good to see an eod/eow close above 124.8 as this confirms a chart breakout. ============================================= Copy of post written elsewhere, IPO, most people are completely missing the significance of 15% founding holding in Oxford Nanopore, so there is plenty more to go for in the share price ONT could overtake Illumina as the world leader in Next [third] Generation Sequencing [NGS]. The company is set to double in size every year for the next four years, according to CEO Gordon Sanghera. At the end of 2020 it represented 32p of each IPO share, at flotation this will at least double. From then onward, the market will be setting the premium. Look at Pacbio [Mcap $6.5bn/revenue $90m] and Illumina [Mcap $56bn/revenue $3.33bn] in the States to get an idea of where this could take the valuation. I have compiled figures for ONT that suggest the income and order value for 2020 will be minmum £275m [approx $375m, 4 times the revenue at Pacb] Furthermore, while Pacb specialises in long reads and Illumina short reads, ONT does both.
30/3/2021
20:32
bamboo2: Just found this from Bloomberg Https://www.bloomberg.com/news/articles/2021-03-30/oxford-nanopore-plans-listing-in-big-boost-to-u-k-ipo-market DNA sequencing firm Oxford Nanopore Technologies Ltd. plans to list on the London Stock Exchange in the second half of the year, delivering a major win for the City in its effort to position itself as an attractive venue for initial public offerings in a post-Brexit world. A listing will give the company access to “deeper, international pools of capital” for its growth plans, Oxford Nanopore said in a statement on its website on Tuesday. The timing of the IPO is dependent on market conditions, it said. IP Group Plc, which owns 15% of Oxford Nanopore, rose 1.5% to 121.80 pence at 12:48 p.m. in London. Oxford Nanopore is worth 2.3 billion pounds based on the valuation that IP Group assigns to its stake. Analysts at Berenberg wrote in a report this month that the Oxford Nanopore “could comfortably” reach a valuation of more than 4 billion pounds in its next fundraising. Oxford Nanopore’s IPO plan comes a day before food-delivery startup Deliveroo Holdings Plc is set to start trading on the LSE. The U.K. is keen to keep its homegrown unicorns from fleeing to the U.S. in search of investors, and is examining an array of new rules including giving founders greater control over their companies even going public, like allowing dual-class share structures on the premium segment of the listing venue. Like other companies tapping the IPO market, Oxford Nanopore, a spinout from the University of Oxford, is listing on the back of a pandemic boost. The company supplies the U.K. with LamPORE tests, which use DNA and RNA sequencing to detect the SARS-CoV-2 virus that causes Covid-19.
30/3/2021
20:24
bamboo2: This is the text from the ONT website Oxford Nanopore Technologies Limited (“the Company”) has today informed its shareholders that it has started the process of preparing for a potential initial public offering (the “IPO”). While the timing of a potential IPO is dependent on market conditions and other matters not fully within the Company’s control, at this stage the Company expects that the IPO would occur in the second half of 2021 on the London Stock Exchange. Oxford Nanopore is driven by a clear ambition: to be a global company that enables the analysis of anything by anyone, anywhere. Our disruptive approach is designed to make biological analysis better, faster, and more accessible & affordable, broadening its potential applications and amplifying its positive impact on society. Today we serve thousands of customers, across a wide range of scientific communities, in more than 100 countries around the world. Scientists are using our DNA/RNA sequencing technology to answer some of society’s most urgent and important questions, including those concerned with biomedical, pathogen, plant and animal scientific research, infectious disease, critical viral surveillance, optimising crop efficiency, ensuring food security and understanding how our environment is changing. Innovation is at our heart. We have built an in-house and licensed portfolio of more than 1,350 patents and applications, and we constantly drive improvements in our technology platform to further enhance our products and their capabilities. Innovation is also central to our manufacturing and in 2019 we opened a high-tech manufacturing facility designed to scale up high quality production capacity for the coming years. We believe that an IPO is the start of the next phase of our journey. Gaining access to deeper, international pools of capital would support our ambitious growth plans, enhancing our ability to innovate and scale our manufacturing and commercial functions. It would, we believe, provide us with the resources and flexibility to fulfil our long-term potential. Why now? In 2015, Oxford Nanopore started to sell its first commercial device, the MinION portable DNA/RNA sequencer. Since then, we have expanded our product range to include both even smaller formats and larger high throughput sequencing devices suitable for population-scale human genomics. The use of nanopore sequencing has expanded in a broad scientific community. More than 1,500 scientific publications now illustrate the use of our technology. We have worked continuously to evolve the technology and build the business since then, however, the last year has been transformative for Oxford Nanopore Technologies. Highlights include: Innovations that enhanced our existing technology platform, which can characterise a broader picture of genetic diversity, at scale, than traditional sequencing technologies. We have released new analysis algorithms, chemistries, and platform improvements that drive even higher performance in both data yields and accuracy. Our technology already provides a unique combination of features in the market: the ability to sequence both short or ultra-long fragments of DNA, the ability to stream sequence data in real time, the ability to sequence the native DNA or RNA molecule and the ability to deploy sequencing in a range of formats from portable pocket-sized devices to ultra-high throughput benchtop machines. In combination with the recently increased performance, we believe that we are at the right point in our journey to scale up our provision of nanopore sequencing to the market. Read more Supporting users around the world to sequence the virus that causes COVID-19, facilitating continual surveillance of the virus. Around a fifth (~170,000) of the SARS-CoV-2 virus genomes in the global database GISAID were generated on one of our devices, with nanopore data uploaded by scientists from more than 85 countries. The role of genomics in infectious disease is now better understood. Maturing our infrastructure around regulated products. Our development of a high-performance diagnostic test for the detection of SARS-CoV-2 drove an acceleration in the development of our infrastructure, processes and talent required to explore opportunities in diagnostic markets beyond COVID-19. This rapid maturation of this part of our business also helps us to prepare for future ‘applied markets’. Manufacturing scale-up. Expansion of our new MinION Building high-tech manufacturing facility in Oxford has prepared us for the next scale of operational growth. These advances made 2020 a pivotal year for us. However, it is clear to us that we are still only in the foothills of what is possible. The challenging events of 2020 demonstrated the importance of life sciences in understanding and improving the world around us. Our DNA and RNA sequencing technology is well-positioned for accelerated use across multiple applications; we believe that there is huge potential for near-sample, rapid, low cost, sequencing-based analyses across scientific research, healthcare and industrial settings. These include the long-term potential to provide rapid biological insights in infectious disease, immune profiling and cancer, as well as in food safety, agriculture or other industrial environments. Most importantly, we sincerely thank our global community of collaborative and innovative customers, our international shareholders and all our colleagues inside the company and in our supply and innovation network for the support in reaching this point. We are looking forward to continuing the journey with you, and getting closer to enabling an Internet of Living Things that has a profoundly positive impact on communities. In the meantime, we remain as focused as ever on continuing to support our customers, innovate and position the company for long-term growth. Dr Gordon Sanghera, CEO
30/3/2021
07:58
bamboo2: IP Group plc - Portfolio company Oxford Nanopore Technologies announces preparation for IPO in the second half of 2021 IP Group plc (LSE: IPO) ("IP Group" or "the Group"), the developer of intellectual property-based businesses, notes that portfolio company Oxford Nanopore Technologies Ltd ("Oxford Nanopore") has today announced that it has informed its shareholders that it has started the process of preparing for a potential Initial Public Offering ("IPO"). Whilst the timing of a potential IPO is dependent on market conditions and other matters not fully within its control, Oxford Nanopore currently expects the IPO to occur in the second half of the year on the London Stock Exchange. IP Group currently holds a direct undiluted beneficial stake of 15.0% in Oxford Nanopore, valued at GBP340.3 million. Oxford Nanopore's announcement is available on the news section of its website.
10/3/2021
08:16
pierre oreilly: Well I never, a 1p Divi.Whenever I suggested a Divi istr pink at my neck telling me to invest in a Divi paying share and not IPO, at incidentally a price 30% less than today.The path is now clear for substantial share price gains - the cash they have can fund an increasing Divi for yonks while still having a big surplus over their seed investment needs.
14/1/2021
15:55
pierre oreilly: IPO doesn't decide how shareholders dispose of their shares. Without any other info, it looks like the 70m shares invesco dumped (probably to cover payments for individuals who are withdrawing from invesco funds) were just absorbed by the market - individuals as well as probably institutions. What is very positive is that 70m can hit the market these days without altering the generally rising share price (which itself is rising due to being hit hard by institutional dumping several months ago when there were less buyers around). We're still rising. It's still way undervalued imv, the discount to nav is far too high even now, let alone on the revaluation for many stocks declared at the next results. We are basically running forwards pretty fast and yet standing still as the assets are revalued. If ipo's board have any concern for their shareholders, then some of the mega and excessive cash pile should be returned to them. A dividend and intention of more would add 25% to the price imv, in addition to the rise correcting the nav discount. I'd like to see their intention of what they'll do with the hundreds of mill they'll get on a nano float.
03/12/2020
15:09
bottomfisher: Today's Artois announcement suggests there might be more value hidden in the lower reaches of IPO's portfolio than the market suspects. However, even after the recent rally, the IPO share price is still trading at a 17% discount to NAV, whilst Draper Esprit (GROW), a fast growing VC rival, trades at a 9% premium and seems to have no difficulty regularly placing £100m plus tranches of shares priced at close to NAV to fund its portfolio of high growth disruptive tech stocks. Interested in any thoughts on which vehicle might make the better long-term investment. Am tempted to go for Draper Esprit but worried that one day IPO will finally surprise its long suffering shareholders on the upside.
10/10/2020
10:43
benchmark: Bamboo - thank you for taking the time to reply with that helpful information. With the announcement that ONT obtained the CE mark for the GridIon & MinIon systems, one would have thought/hoped that it would have been reflected in the IPO share price yesterday afternoon. The fact that it wasn't suggests measured selling into any perceived rise?
Ip share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
IPO
Ip
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210419 04:18:15